Redeye leaves a comment following Alzinova’s announcement of entering a Memorandum of Understanding (MoU) with a leading Saudi healthcare provider regarding the potential co-development and investment in ALZ-101 and ALZ-201. We view this unexpected strategic pivot as an intriguing option that could secure funding pathways for the upcoming phase II trial, though we emphasize that the agreement currently remains non-binding.
LÄS MER
